Faecal microbiota transplantation for patients with diabetes type 1 and severe gastrointestinal neuropathy (FADIGAS): a randomised, double-blinded, placebo-controlled trial

Keyphrases

• Neuropathy 100%
• Placebo-controlled Trial 100%
• Patients with Diabetes 100%
• Gastrointestinal 100%
• Diabetes Type 1 100%
• Fecal Microbiota Transplantation 100%
• Placebo 60%
• Adverse Events 40%
• Gastrointestinal Diseases 30%
• Type I Diabetes 30%
• Type 1 Diabetes Mellitus (T1DM) 30%
• Diarrhea 20%
• Bloating 20%
• Irritable Bowel Syndrome 20%
• Trial Registration 10%
• Quality of Life 10%
• Placebo Groups 10%
• Clinical Outcomes 10%
• Abdominal Pain 10%
• Placebo-controlled 10%
• Moderate to Severe 10%
• Current Therapies 10%
• Symptom Severity 10%
• Serious Adverse Events 10%
• Patient Assessment 10%
• Bowel Dysfunction 10%
• Nausea-vomiting 10%
• Glycerol 10%
• Constipation 10%
• Feces 10%
• Gastrointestinal Symptom Rating Scale 10%
• Steno 10%
• Severity Index 10%
• Common Terminology Criteria for Adverse Events (CTCAE) 10%
• Impact Scale 10%
• Diabetic Enteropathy 10%
• Public Trial 10%
• Food Color 10%
• Severity Grading 10%
• Gastroenteropathy 10%

Medicine and Dentistry

• Patient with Type 1 Diabetes 100%
• Neuropathy 100%
• Fecal Microbiota Transplantation 100%
• Placebo 100%
• Adverse Event 60%
• Gastrointestinal Distress 40%
• Diarrhea 20%
• Gastrointestinal Disease 20%
• Bloating 20%
• Irritable Bowel Syndrome 20%
• Insulin Dependent Diabetes Mellitus 10%
• Single Drug Dose 10%
• Patient Assessment 10%
• Nausea 10%
• Constipation 10%
• Abdominal Pain 10%
• Quality of Life 10%
• Feces 10%
• Table Salt 10%
• Rating Scale 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Feces microflora 100%
• Placebo 100%
• Neuropathy 100%
• Insulin Dependent Diabetes Mellitus 100%
• Adverse Event 60%
• Gastrointestinal Symptom 40%
• Irritable Colon 20%
• Diarrhea 20%
• Gastrointestinal Disease 20%
• Bloating 20%
• Nausea 10%
• Constipation 10%
• Abdominal Pain 10%
• Table Salt 10%